Estimated Glomerular Filtration Rate and Systolic Time Intervals in Risk Stratification for Increased Left Ventricular Mass Index and Left Ventricular Hypertrophy

Wen-Hsien Lee, MD, Po-Chao Hsu, MD, PhD, Chun-Yuan Chu, MD, Szu-Chia Chen, MD, Hung-Hao Lee, MD, Meng-Kuang Lee, MD, Chee-Siong Lee, MD, Hsueh-Wei Yen, MD, Tsung-Hsien Lin, MD, PhD, Wen-Chol Voon, MD, Wen-Ter Lai, MD, Sheng-Hsiu Sheu, MD, and Ho-Ming Su, MD

Abstract: Either decreased renal function or increased systolic time interval is associated with cardiac hypertrophy and poor cardiac outcome. The aim of this study was to evaluate combination of renal function and brachial systolic time intervals associated with increased left ventricular mass index (LVMI) and left ventricular hypertrophy (LVH).

In total of 990 patients were consecutively included in this study from January 2011 to December 2012. All study participants were further classified into 4 groups by the values of estimated glomerular filtration rate (eGFR) and ratio of brachial preejection period (bPEP) to brachial ejection time (bET). The classification of 4 groups were eGFR ≥ 45 ml/min/1.73 m² and bPEP/bET < 0.38 (group 1), eGFR ≥ 45 ml/min/1.73 m² and bPEP/bET ≥ 0.38 (group 2), eGFR < 45 ml/min/1.73 m² and bPEP/bET < 0.38 (group 3), and eGFR < 45 ml/min/1.73 m² and bPEP/bET ≥ 0.38 (group 4), respectively. Patients in groups 1 and 4 had the lowest and highest LVMI among 4 groups, respectively (P < 0.001). In multivariable analyses, increased LVMI and LVH were significantly associated with patients in groups 2, 3 and 4 (vs group 1) (P < 0.019).

Our study demonstrated that joined parameter of renal function and systolic time intervals, in terms of eGFR and bPEP/bET, might be an alternative method in risk stratification for increased LVMI and LVH.

(International Journal of Cardiology 95(10):e2917)

Abbreviations: ARBs = angiotensin II receptor blockers, bET = brachial ejection time, bPEP = brachial preejection period, CaMK = calcium/calmodulin-dependent kinase, CCBs = calcium channel blockers, CKD = chronic kidney disease, E = transmital E wave velocity, Ea = early diastolic mitral velocity, eGFR = estimated glomerular filtration rate, GPIIIA PlA2 = glycoprotein IIIa protein with platelet antigen 2, GRKs = G-protein-coupled receptor kinases, IVSTd = interventricular septal wall thickness in diastole, LVEF = left ventricular ejection fraction, LVH = left ventricular hypertrophy, LVId = left ventricular internal diameter in diastole, LVMI = left ventricular mass index, LVPWd = left ventricular posterior wall thickness in diastole, NFκB = nuclear factor-κB.

INTRODUCTION

Abnormal cardiac and vascular structure and function are increased the risk of cardiovascular mobility and mortality.1 Most studies pay much attention to left ventricular hypertrophy (LVH) because of development of heart failure and high cardiovascular death.2–4 The mechanisms associated with LVH are multifactors. Either cardiac volume or pressure overload triggers several biological signal cascades leading to cardiac hypertrophy.2 Meanwhile, either arterial pressure or fluid volume overload are common noted in patients with chronic kidney disease (CKD), which can contribute to abnormal cardiac geometry and function in these patients. In epidemiological studies, advanced CKD patients had a high prevalence of LVH.5,6 The prevalence of LVH is inversely proportional to the value of eGFR.7,8 CKD patients, who either have reduced estimated glomerular filtration rate (eGFR) or renal damage, frequently have volume retention and electrolyte imbalance which may cause abnormal cardiac function, increased left ventricular mass index (LVMI), and adverse cardiac events. Prior studies demonstrated that reduced eGFR was the important factor affecting not only the progression of renal disease but also abnormal left ventricular geometry.7,8

On the opposite hand, preexisting cardiac disease is also associated with renal damage and rapid deterioration of eGFR.9 The relationship between renal and cardiac disease is close and bidirectional.10 Parameters of cardiac systolic function can be measured from echocardiography and peripheral arterial Doppler waveform.11–13 Systolic time intervals, including preejection period and ejection time, are a well-known indicator for global cardiac systolic function.14 Brachial preejection period (bPEP) and brachial ejection time (bET) calculated from waveform of brachial arterial pressure, electrocardiogram and phono cardiogram were alternative parameters for evaluation of left ventricular systolic function.14 In our previous studies, prolonged bPEP, short bET, and high bPEP/bET were associated with cardiac systolic dysfunction.12,15 Furthermore, bPEP/bET
can serve as a useful parameter in prediction of LVH and cardiac death in patients with CKD and hemodialysis.\(^{15–17}\)

Although deterioration of renal function and brachial systolic time intervals, in terms of decreased of eGFR and high bPEP/bET, have significant associated with LVH, there was no study investigated LVH from combining these 2 important indicators. We hypothesized that mixed parameters of renal function and brachial systolic time intervals were useful tools in the risk classification for LVH. The goal of our study was to evaluate the role of joined with eGFR and bPEP/bET in risk categorization for increased LVMi and LVH.

**METHODS**

**Study Subjects and Design**

Study participants were enrolled for echocardiographic survey in a regional hospital in Taiwan owing to suspected cardiovascular disease from January 2011 to December 2012 (Figure 1). Study participants were excluded due to atrial fibrillation, significant valvular heart disease, complete left bundle branch block, or poor image visualization. Finally, total 990 patients were enrolled for echocardiographic and bPEP/bET examination. The study design was approved by the institutional review board of the Kaohsiung Medical University Hospital (KMUH-IRB-20140256).

**Echocardiographic Assessment**

All study patients were received echocardiographic examination by a standard protocol.\(^{12,18}\) A single experienced cardiologist performed all echocardiographic examination and acquired image using the Vivid 7 (General Electrics, Horten, Norway). From standard transthoracic view, we measured left ventricular internal diameter (LVID), interventricular septal wall thickness (IVST), and left ventricular posterior wall thickness (LVPWT) in the end left ventricular diastolic phase. The Doppler and tissue Doppler parameters, such as transmitral E wave velocity (E), E-wave deceleration time, transmitral A wave velocity, and early diastolic mitral velocity (Ea), were

---

**FIGURE 1.** Flow chart of study patients. bPEP/bET = brachial preejection period/brachial ejection time; eGFR = estimated glomerular filtration rate.
measured from standard apical four-chamber view.\textsuperscript{18} We calculated left ventricular ejection fraction (LVEF) and Left ventricular mass by the modified Simpson method and the Devereux-modified method, respectively.\textsuperscript{19} LVMI was calculated by dividing left ventricular mass by body surface area. In the present study, we defined LVH as LVMI more than 115 g/m\textsuperscript{2} in men and more than 95 g/m\textsuperscript{2} in women.\textsuperscript{18} All echocardiographic parameters were acquired from 3 continued beats and measured from offline EchoPAC software by a single experienced cardiologist.

**Measurement of Blood Pressures, bPPE, and bET**

All blood pressures, bPPE, and bET measurements were obtained after echocardiographic examination. The bPPE, bET, and ratio of bPPE/bET were calculated from an ABI-form device (VP1000) by a standard measurement.\textsuperscript{12,20}

**Collection of Medical Characteristics and Laboratory Data**

Baseline medication, personal characteristic, and laboratory data were collected from medical records. The value of eGFR was calculated by the equation of Modification of Diet in Renal Disease study.\textsuperscript{21}

**Classification of Study Population**

The study participants were divided into 4 groups by the values of eGFR and bPPE/bET. Patients were classified into 4 groups when their eGFR $\geq$ 45 mL/min/1.73 m\textsuperscript{2} and bPPE/bET $<$ 0.38 (group 1), eGFR $\geq$ 45 mL/min/1.73 m\textsuperscript{2} and bPPE/bET $\geq$ 0.38 (group 2), eGFR $< 45$ mL/min/1.73 m\textsuperscript{2} and bPPE/bET $<$ 0.38 (group 3), and eGFR $< 45$ mL/min/1.73 m\textsuperscript{2} and bPPE/bET $\geq$ 0.38 (group 4).\textsuperscript{12}

### Statistical Analysis

Statistical analysis was calculated by SPSS 18.0 (SPSS, Inc., Chicago, State of Illinois). The baseline, laboratory, and echocardiographic data were presented as percentage or mean $\pm$ standard deviation. Four study groups were analyses by 1-way analysis of variance and Bonferroni post hoc test. Among study groups, group 1 was taken as reference category. Variables which were significance in univariate analysis were selected into multivariable linear and logistic analyses for determinants of LVMI and LVH, respectively. The statistical difference was considered when the P-value $<0.05$.

### RESULTS

A total of 990 patients were divided into 541, 236, 142, and 71 patients in groups 1, 2, 3, and 4, respectively. The differences of clinical data and echocardiographic parameters among four study groups are shown in Tables 1 and 2. Compared with patients in group 1 (LVMI = 126.6 $\pm$ 33.4 g/m\textsuperscript{2}, LVH = 69.8%), patients in group 2 (LVMI = 141.6 $\pm$ 45.8 g/m\textsuperscript{2}, LVH = 74.2%), group 3 (LVMI = 148.5 $\pm$ 45.2 g/m\textsuperscript{2}, LVH =

### TABLE 1. Clinical Characteristics of Patients Among Study Groups

|                     | Group 1 (n = 541) | Group 2 (n = 236) | Group 3 (n = 142) | Group 4 (n = 71) | P       |
|---------------------|-------------------|-------------------|-------------------|-----------------|---------|
| **Age (y)**         | 62.4 $\pm$ 12.9   | 57.6 $\pm$ 13.1   | 70.5 $\pm$ 11.1   | 64.6 $\pm$ 13.0 | $<0.001$|
| **Male gender (%)** | 52.3              | 68.6              | 43.7              | 66.2            | $<0.001$|
| **Smoking history (%)** | 15.7            | 23.7              | 7.7              | 21.7            | $<0.001$|
| **Diabetes mellitus (%)** | 24.5            | 23.7              | 50.0              | 43.7            | $<0.001$|
| **Hypertension (%)** | 72.9              | 66.4              | 84.5            | 81.7            | 0.001   |
| **Coronary artery disease (%)** | 17.7            | 20.3              | 17.6              | 16.9            | 0.817   |
| **Cerebrovascular disease (%)** | 6.4            | 7.6               | 10.6             | 1.4             | 0.085   |
| **Systolic blood pressure (mmHg)** | 133.9 $\pm$ 18.3 | 132.3 $\pm$ 19.4  | 143.8 $\pm$ 24.0  | 143.2 $\pm$ 24.4 | $<0.001$|
| **Diastolic blood pressure (mmHg)** | 75.2 $\pm$ 10.1  | 79.6 $\pm$ 12.0   | 74.2 $\pm$ 12.2   | 82.6 $\pm$ 15.5  | $<0.001$|
| **Pulse pressure (mmHg)** | 58.5 $\pm$ 12.8   | 52.7 $\pm$ 11.4  | 69.6 $\pm$ 15.8  | 60.9 $\pm$ 14.9  | $<0.001$|
| **Heart rate (beats/min)** | 67.5 $\pm$ 10.9  | 73.5 $\pm$ 11.9  | 65.8 $\pm$ 10.1  | 75.8 $\pm$ 14.0  | $<0.001$|
| **Body mass index (kg/m\textsuperscript{2})** | 26.1 $\pm$ 3.6   | 26.8 $\pm$ 3.9   | 26.2 $\pm$ 4.1   | 26.2 $\pm$ 4.5   | 0.135   |
| **bPPE/bET**        | 0.32 $\pm$ 0.04   | 0.45 $\pm$ 0.07** | 0.30 $\pm$ 0.04** | 0.48 $\pm$ 0.10* | $<0.001$|
| **Antihypertensive medication use (%)** | 77.2            | 75.0              | 89.4              | 87.3            | 0.001   |
| **ACEI (%)**        | 10.7              | 16.5              | 5.6              | 4.2             | 0.002   |
| **ARB (%)**         | 46.7              | 42.4              | 62.7            | 50.7            | 0.001   |
| **β-blocker (%)**   | 41.8              | 39.0              | 54.9            | 47.9            | 0.013   |
| **Calcium channel blocker (%)** | 38.6          | 31.4              | 64.1            | 53.5            | $<0.001$|
| **Diuretics (%)**   | 23.3              | 34.7              | 43.7            | 52.1            | $<0.001$|

**Laboratory parameters**

|                       | Group 1 (n = 541) | Group 2 (n = 236) | Group 3 (n = 142) | Group 4 (n = 71) | P       |
|-----------------------|-------------------|-------------------|-------------------|-----------------|---------|
| **Fasting glucose (mg/dL)** | 111.8 $\pm$ 36.3 | 114.2 $\pm$ 41.4  | 119.0 $\pm$ 37.9  | 126.1 $\pm$ 54.6 | 0.046   |
| **Triglyceride (mg/dL)** | 137.5 $\pm$ 82.1  | 165.1 $\pm$ 119.9 | 151.8 $\pm$ 87.7  | 188.8 $\pm$ 147.7 | $<0.001$|
| **Total cholesterol (mg/dL)** | 191.3 $\pm$ 38.2 | 194.2 $\pm$ 43.8  | 185.8 $\pm$ 42.4  | 184.8 $\pm$ 42.8 | 0.205   |
| **Baseline eGFR (mL/min/1.73 m\textsuperscript{2})** | 66.6 $\pm$ 12.9  | 68.2 $\pm$ 14.2   | 29.7 $\pm$ 11.1   | 28.2 $\pm$ 11.8  | $<0.001$|

ACEI = angiotensin-converting-enzyme inhibitor; ARB = angiotensin II receptor blocker; bPPE = brachial pre-ejection period; bET = brachial ejection time, eGFR = estimated glomerular filtration rate.

* $P < 0.05$ compared with group 1.

** $P < 0.05$ compared with group 2.

*** $P < 0.05$ compared with group 3.
In the univariate analysis, age, male gender, smoking, diabetes, hypertension, cerebrovascular disease, systolic blood pressure, body mass index, using of angiotensin II receptor blockers (ARBs), β-blockers, calcium channel blockers (CCBs) and

| TABLE 3. Determinants of LVMI in Study Subjects |
|-----------------------------------------------|
| In the univariate analysis, age, male gender, smoking, diabetes, hypertension, cerebrovascular disease, systolic blood pressure, body mass index, using of angiotensin II receptor blockers (ARBs), β-blockers, calcium channel blockers (CCBs) and |

**TABLE 2. Echocardiographic Characteristics of Patients Among Study Groups**

| Group 1 (n = 541) | Group 2 (n = 236) | Group 3 (n = 142) | Group 4 (n = 71) | P   |
|------------------|------------------|------------------|------------------|-----|
| LAD (mm)         | 36.5 ± 5.4       | 37.3 ± 6.5       | 39.1 ± 5.6***   | 39.0 ± 6.8* | <0.001|
| LVESD (mm)       | 49.8 ± 5.8       | 53.1 ± 8.7*      | 51.9 ± 6.2*     | 56.4 ± 8.6*** | <0.001|
| LVMI (%)         | 89.4%            | 92.3%            | 92.7%           | 92.7%     | <0.001|
| E (cm/s)         | 72.3 ± 16.8      | 61.2 ± 19.7*     | 78.9 ± 27.8***  | 63.2 ± 22.1* | <0.001|
| A (cm/s)         | 80.2 ± 19.6      | 71.9 ± 18.0*     | 92.7 ± 23.0***  | 83.8 ± 27.9*** | <0.001|
| E/A              | 0.96 ± 0.36      | 0.95 ± 0.56      | 0.89 ± 0.41     | 0.83 ± 0.43 | 0.069 |
| E-wave deceleration time (ms) | 207.1 ± 60.3 | 204.3 ± 62.5 | 232.9 ± 72.3*** | 212.8 ± 82.7 | <0.001|
| Ea (cm/s)        | 9.4 ± 3.0        | 8.1 ± 3.1*       | 7.4 ± 2.5*      | 6.4 ± 2.6*** | <0.001|
| E/Ea             | 8.6 ± 4.1        | 8.7 ± 4.8        | 11.7 ± 5.1***   | 11.3 ± 5.9*** | <0.001|
| LVMI (%)         | 69.8             | 74.2*            | 84.4***         | 88.7***    | <0.001|
| LVH (%)          | 89.4%            | 89.4%            | 89.4%           | 89.4%     | <0.001|
| **LVH (%)**      | **89.4%**        | **89.4%**        | **89.4%**       | **89.4%** | <0.001|

A = transmitral A wave velocity; E = transmitral E wave velocity; Ea = early diastolic mitral annulus velocity; E/Ea = E-wave deceleration time; LVEF = left ventricular ejection fraction; LVDD = left ventricular diastolic dysfunction; LVESD = left ventricular end-diastolic dimension; LVH = left ventricular hypertrophy; LVMI = left ventricular mass index.

*P < 0.05 compared with group 1.
**P < 0.05 compared with group 2.
***P < 0.05 compared with group 3.

89.4 %), and group 4 (LVMI = 181.9 ± 57.1 g/m², LVH = 88.7%) had a higher LVMI (P < 0.001) and higher prevalence of LVH (P ≤ 0.041). Table 3 shows the determinants of LVMI in all study participants by univariate and multivariate analyses.
TABLE 4. Determinants of LVH in Study Subjects

|                     | Univariate          | P      | Multivariate         | P      |
|---------------------|---------------------|--------|----------------------|--------|
| Odds Ratio (95% CI) |                     |        | Odds Ratio (95% CI)  |        |
| Age (per 1 y)       | 1.027 (1.015, 1.038)| <0.001 | 1.017 (1.004, 1.031) | 0.009  |
| Male gender         | 0.652 (0.485, 0.876)| 0.005  | 0.694 (0.498, 0.966) | 0.030  |
| Smoking history     | 0.935 (0.651, 1.396)| 0.953  | —                    | —      |
| Diabetes mellitus   | 1.630 (1.164, 2.284)| 0.004  | 1.201 (0.815, 1.770) | 0.354  |
| Hypertension        | 2.158 (1.585, 2.939)| <0.001 | 1.070 (0.709, 1.614) | 0.747  |
| Coronary artery disease | 1.216 (0.827, 1.787)| 0.319  | —                    | —      |
| Cerebrovascular disease | 1.216 (0.673, 2.195)| 0.517  | —                    | —      |
| Systolic blood pressure (per 1 mmHg) | 1.028 (1.019, 1.036) | <0.001 | 1.024 (1.015, 1.034) | <0.001 |
| Heart rate (per 1 beat/min) | 0.979 (0.967, 0.991) | 0.001  | 0.972 (0.959, 0.986) | <0.001 |
| Body mass index (per 1/m²) | 1.085 (1.043, 1.130) | <0.001 | 1.086 (1.037, 1.137) | <0.001 |
| Medication          |                     |        |                      |        |
| ACEI                | 1.347 (0.823, 2.203)| 0.236  | —                    | —      |
| ARB                 | 1.638 (1.223, 2.196)| 0.001  | 0.916 (0.634, 1.323) | 0.641  |
| β-blocker           | 1.773 (1.311, 2.397)| <0.001 | 1.402 (0.994, 1.977) | 0.054  |
| Calcium channel blocker | 2.012 (1.477, 2.740) | <0.001 | 1.356 (0.929, 1.980) | 0.114  |
| Diuretics           | 2.433 (1.703, 3.475)| <0.001 | 1.695 (1.130, 2.543) | 0.011  |
| Laboratory parameters|                   |        |                      |        |
| Fasting glucose (per 1 mg/dL) | 1.000 (0.996, 1.004) | 0.949  | —                    | —      |
| Triglyceride (per 1 mg/dL) | 1.000 (0.999, 1.002) | 0.861  | —                    | —      |
| Total cholesterol (per 1 mg/dL) | 1.000 (0.996, 1.003) | 0.820  | —                    | —      |
| Study groups        |                     |        |                      |        |
| Group 1             | Reference            |        | Reference            |        |
| Group 2             | 1.241 (0.880, 1.751)| 0.218  | 1.602 (1.086, 2.364) | 0.017  |
| Group 3             | 3.664 (2.081, 6.450)| <0.001 | 2.094 (1.132, 3.874) | 0.019  |
| Group 4             | 3.408 (1.597, 7.273)| 0.002  | 3.213 (1.394, 7.407) | 0.006  |

ACEI = angiotensin-converting-enzyme inhibitor; ARB = angiotensin II receptor blocker; CI = confidence interval; LVH = left ventricular hypertrophy.

DISCUSSION

In the present study, we demonstrated that combination of eGFR and bP/Ep/bET were useful in risk stratification for increased LVMI and LVH. Patients in group 1 (higher eGFR and lower bP/Ep/bET) and patients in group 4 (lower eGFR and higher bP/Ep/bET) had the lowest and highest LVMI among 4 groups, respectively. In addition, compared to patients in group 1, the other groups were associated with a higher LVMI and higher prevalence of LVH in the multivariate analysis.

Boudoulas et al. 22 showed significantly correlation between the ratio of systolic time intervals and LVMI in patients with hypertension. Our previous studies had demonstrated that bP/Ep/bET was a significant parameter in prediction of decreased LVEF and increased LVMI.20-23 The main aim of the present study was to compare LVMI and LVH among 4 groups divided by eGFR and bP/Ep/bET. Compared with reference group (group 1), we found patients with higher bP/Ep/bET and/or lower eGFR had an increased LVMI and high prevalence of LVH. These results might suggest patients with relatively normal cardiorenal function had a low LVMI and LVH, but patients with cardiorenal dysfunction had a high LVMI and LVH. Hence, classification of patients into 4 groups using eGFR and bP/Ep/bET might be useful in recognizing patients with increased LVMI and LVH.

Cardiac and renal failure may interact each other and influence cardiac and renal outcomes.24 Mechanisms of cardio-renal interaction may include impaired endothelial function, anemia, systemic inflammation, increased active oxygen species or activation of adrenergic nervous system and rennin–angiotensin system.24-25 Pressure and volume overload are frequently noted in CKD patients, which can contribute to...
LVH and abnormal left ventricular function in these patients. In fact, CKD patients have a high prevalence of increased LVMi and LVH.5,26

The causes of cardiac hypertrophy were multifactors. Growth of myocardial mass was influenced by various neurohormones, growth factors, and circulatory cytokines.27 High arterial pressure and atherosclerotic process serve important roles in cardiac hypertrophy and its sequentially adverse cardiac events.28 Recently, several studies showed genetic factors of arterial pressure and atherosclerotic process serve important tension.31 In bench studies, different G-protein-coupled receptors, especially GRK2, played an important role in essential hypertension.32 In in vitro studies, Sorriento and Cipolletta et al and Ersilia et al demonstrated that CaMK4 gene deletion was an important predictor for cardiac death (odds ratio = 9.594) in patients with atherosclerotic coronary artery diseases.30 Some possible molecular mechanisms, including vascular endothelial dysfunction, sympathetic nervous activation, G-protein-coupled receptor kinase (GRK) expression, and calcium/calmodulin-dependent kinase (CaMK) regulation, were associated with high arterial pressure.31 The GRKs family, especially GRK2, played an important role in essential hypertension.33 In bench studies, different G-protein-coupled receptors, such as β-adrenergic receptor and angiotensin II type 1A receptor, were regulated by GRK2.31–33 Recently, both in vivo and in vitro studies, Sorriento and Cipolletta et al and Ersilia et al demonstrated that GRK2-mediated cardiac hypertrophy through nuclear factor-κB (NFκB) and extracellular regulated kinase pathway, respectively.34,35 Besides GRK2, GRK5 also regulated cardiac hypertrophy from NFkB signal transduction.36 Additionally, the family of CaMKs and their genes were associated with hypertension and cardiac hypertrophy. Santulli et al demonstrated that CaMK4 gene deletion was an important role in regulation of vascular pressure through inactivation of endothelial nitric oxide synthase.37 There were several limitations to our study. First, our study was a cross-sectional design, was performed only in 1 regional hospital and lacked follow up, which limited our study strength. Second, there was no validation of bP/E/bET in patients with atrial fibrillation and valvular heart diseases. Therefore, our results could not be applied in these patients. Finally, we did not check gene polymorphisms in our patients. Hence, the genetic consideration and molecular signal transduction about cardiac hypertrophy were lack in this study.

In conclusion, separating patients into four groups using eGFR and bP/E/bET might be an alternative method in risk stratification for increased LVMi and LVH.

REFERENCES

1. Cuspidi C, Meani S, Valerio C, et al. Left ventricular hypertrophy and cardiovascular risk stratification: impact and cost-effectiveness of echocardiography in recently diagnosed essential hypertensives. J Hypertens. 2006;24:1671–1677.

2. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation. 2000;102:470–479.

3. Chahal NS, Lim TK, Jain P, et al. New insights into the relationship of left ventricular geometry and left ventricular mass with cardiac function: a population study of hypertensive subjects. Eur Heart J. 2010;31:588–594.

4. Myerson SG, Montgomery HE, World MJ, et al. Left ventricular mass: reliability of m-mode and 2-dimensional echocardiographic formulas. Hypertension. 2002;40:673–678.

5. Paoletti E, Bellino D, Cassottana P, et al. Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis. 2005;46:320–327.

6. Tucker B, Fabbian F, Giles M, et al. Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure. Nephrol Dial Transplant. 1997;12:724–728.

7. Paoletti E. Left ventricular hypertrophy and progression of chronic kidney disease. J Nephrol. 2012;25:847–850.

8. Nardi E, Palermo A, Mule G, et al. Left ventricular hypertrophy and geometry in hypertensive patients with chronic kidney disease. J Hypertens. 2009;27:633–641.

9. Elsayed EF, Tighiouart H, Griffith J, et al. Cardiovascular disease and subsequent kidney disease. Arch Intern Med. 2007;167:1130–1136.

10. Tsuruya K, Eriguchi M. Cardiorenal syndrome in chronic kidney disease. Curr Opin Nephrol Hypertens. 2015;24:154–162.

11. Van de Werf F, Piessens J, Kesteloot H, et al. A comparison of systolic time intervals derived from the central aortic pressure and from the external carotid pulse tracing. Circulation. 1975;51:310–316.

12. Su HM, Lin TH, Hsu PC, et al. A comparison between brachial and echocardiographic systolic time intervals. PLoS One. 2013;8:e55840.

13. Polak JF, Alessi-Chinetti JM, Estes JM, et al. Left ventricular ejection time derived from the common carotid artery Doppler waveform: association with left ventricular ejection fraction and prediction of heart failure. J Ultrasound Med. 2015;34:1237–1242.

14. Gillebert TC, Van de Veire N, De Buyzere ML, et al. Time intervals and global cardiac function. Use and limitations. Eur Heart J. 2005;25:2185–2186.

15. Chen SC, Chang JM, Liu WC, et al. Significant correlation between ratio of brachial pre-ejection period to ejection time and left ventricular ejection fraction and mass index in patients with chronic kidney disease. Nephrol Dial Transplant. 2011;26:1895–1902.

16. Chen SC, Chang JM, Tsai JC, et al. A systolic parameter defined as the ratio of brachial pre-ejection period to brachial ejection time predicts cardiovascular events in patients with chronic kidney disease. Circ J. 2010;74:2206–2210.

17. Chen SC, Chang JM, Tsai JC, et al. A new systolic parameter defined as the ratio of brachial pre-ejection period to brachial ejection time predicts overall and cardiovascular mortality in hemodialysis patients. Hypertens Res. 2010;33:492–498.

18. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440–1463.

19. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450–458.

20. Su HM, Lin TH, Lee CS, et al. Myocardial performance index: a feasible parameter in evaluation of cardiac performance. Use and limitations. Eur Heart J. 2000;21:2439–2445.

21. Vickery S, Stevens PE, Dalton RN, et al. Does the id-ms traceable MDRD equation work and is it suitable for use with compensated jaffe and enzymatic creatinine assays? Nephrol Dial Transplant. 2006;21:2439–2445.

22. Boudoulas H, Mantzoratos D, Sohn VH, et al. Left ventricular mass and systolic performance in chronic systemic hypertension. Am J Cardiol. 1986;57:232–237.
23. Su HM, Lin TH, Hsu PC, et al. Impact of systolic time intervals on the relationship between arterial stiffness and left ventricular hypertrophy. *Atherosclerosis*. 2012;223:171–176.

24. Bock JS, Gottlieb SS. Cardiorenal syndrome: new perspectives. *Circulation*. 2010;121:2592–2600.

25. Bruch C, Rothenburger M, Gotzmann M, et al. Chronic kidney disease in patients with chronic heart failure—impact on intracardiac conduction, diastolic function and prognosis. *Int J Cardiol*. 2007;118:375–380.

26. Stewart GA, Gansevoort RT, Mark PB, et al. Electrocardiographic abnormalities and uremic cardiomyopathy. *Kidney Int*. 2005;67:217–226.

27. Selvetella G, Lembo G. Mechanisms of cardiac hypertrophy. *Heart Fail Clin*. 2005;1:263–273.

28. Nadruz W. Myocardial remodeling in hypertension. *J Hum Hypertens*. 2015;29:1–6.

29. Lanni F, Santulli G, Izzo R, et al. The Pi (A1/A2) polymorphism of glycoprotein IIIa and cerebrovascular events in hypertension: increased risk of ischemic stroke in high-risk patients. *J Hypertens*. 2007;25:551–556.

30. Galasso G, Santulli G, Piscione F, et al. The GPIIIa pla2 polymorphism is associated with an increased risk of cardiovascular adverse events. *BMC Cardiovasc Disord*. 2010;10:41.

31. Santulli G, Trimarco B, Iaccarino G. G-protein-coupled receptor kinase 2 and hypertension: molecular insights and pathophysiological mechanisms. *High Blood Press Cardiovasc Prev*. 2013;20:5–12.

32. Ferguson SS, Feldman RD. Beta-adrenoceptors as molecular targets in the treatment of hypertension. *Can J Cardiol*. 2014;30:S3–S8.

33. Kim J, Ahn S, Ren XR, et al. Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling. *Proc Natl Acad Sci*. 2005;102:1442–1447.

34. Sorrentino D, Santulli G, Franco A, et al. Integrating GRK2 and NFkappaB in the pathophysiology of cardiac hypertrophy. *J Cardiovasc Transl Res*. 2015;8:493–502.

35. Cipolletta E, Rusciano MR, Maione AS, et al. Targeting the CaMKII/ERK interaction in the heart prevents cardiac hypertrophy. *PLoS One*. 2015;10:e0130477.

36. Sorrentino D, Santulli G, Fusco A, et al. Intracardiac injection of adGRK5-NT reduces left ventricular hypertrophy by inhibiting NF-kappaB-dependent hypertrophic gene expression. *Hypertension*. 2010;56:696–704.

37. Santulli G, Cipolletta E, Sorrentino D, et al. CaMK4 gene deletion induces hypertension. *J Am Heart Assoc*. 2012;1:e001081.